Targeting Patients Undergoing Angioplasty for Thrombus Inhibition | Zendy

William S. Weintraub | Zendy; Trevor Thompson | Zendy; Steven D. Culler | Zendy; Stephen J. Boccuzzi | Zendy; Edmund R. Becker | Zendy; Andrzej S. Kosinski | Zendy; Elizabeth M. Mahoney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting Patients Undergoing Angioplasty for Thrombus Inhibition

Author(s) -

William S. Weintraub,

Trevor Thompson,

Steven D. Culler,

Stephen J. Boccuzzi,

Edmund R. Becker,

Andrzej S. Kosinski,

Elizabeth M. Mahoney

Publication year - 2000

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.102.4.392

Subject(s) - medicine , myocardial infarction , adverse effect , revascularization , angioplasty , cost effectiveness , emergency medicine , thrombus , cardiology , surgery , intensive care medicine , risk analysis (engineering)

In recent clinical trials, glycoprotein IIb/IIIa blockers have demonstrated effectiveness in preventing adverse events after angioplasty in high-risk patients. However, uncertainty exists regarding the cost-effective selection of patients to receive antiplatelet therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research